Lifecome Biochemistry Co Ltd - Asset Resilience Ratio
Lifecome Biochemistry Co Ltd (002868) has an Asset Resilience Ratio of 4.69% as of September 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 002868 liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2019)
This chart shows how Lifecome Biochemistry Co Ltd's Asset Resilience Ratio has changed over time. See net assets of Lifecome Biochemistry Co Ltd for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Lifecome Biochemistry Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Lifecome Biochemistry Co Ltd market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥45.35 Million | 4.69% |
| Total Liquid Assets | CN¥45.35 Million | 4.69% |
Asset Resilience Insights
- Limited Liquidity: Lifecome Biochemistry Co Ltd maintains only 4.69% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Lifecome Biochemistry Co Ltd Industry Peers by Asset Resilience Ratio
Compare Lifecome Biochemistry Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Lifecome Biochemistry Co Ltd (2019–2019)
The table below shows the annual Asset Resilience Ratio data for Lifecome Biochemistry Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-12-31 | 17.13% | CN¥173.03 Million ≈ $25.32 Million |
CN¥1.01 Billion ≈ $147.80 Million |
-- |
About Lifecome Biochemistry Co Ltd
Lifecome Biochemistry Co.,Ltd. operates as a biopharmaceutical company in China. It offers bacitracin zinc products, colistin sulfate products, probiotics products, bacitracin methylene disalicylate products, biological preservatives, photovoltaic film products, etc.; veterinary drugs; and food preservatives. The company was founded in 2003 and is based in Pucheng, China.